Furthermore, Chromogranin A does not provide an additive benefit to standard surveillance for predicting the presence of SDHB- or SDHD-related paraganglioma but has a useful negative predictive value when normal in patients with an SDHB mutation [46]. This evidence concerns the gene CHGA and paraganglioma.